Stemirna Therapeutics Co., Ltd. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2016

Location

Shanghai China

Primary Industry

Biotechnology

About

Based in Shanghai, China, and established in 2016, Stemirna Therapeutics Co., Ltd. is a biotechnology company that specializes in mRNA technology. Li Hangwen is the founder and current CEO of the company. It has partnerships with Baidu USA Research Institute, Oregon State University, and the University of Rochester. Following the venture funding in June 2021, the company plans to use the proceeds to finance clinical trials and the production of its COVID-19 vaccine candidate. In May 2023, t raised an undisclosed amount of pre-series D funding from other unspecified investors. The company has 50,000 square meters of vaccine production base and 400 million doses of vaccine capacity as of 2023. The company focuses on developing and providing mRNA (mRNA stands for messenger RNA, it is the information carrier in the process of gene expression) drugs for different diseases, including cancer, contagion, and a genetic disorder. The company's platforms include an mRNA synthesis platform, an LPP (ipopolyplex) delivery platform, and GMP manufacturing (GMP-compliant facilities for manufacturing and quality control). The company has also developed a pipeline that spans different therapeutic areas, including immuno-oncology, infectious diseases, and iPSC, based on its mRNA synthesis platform and LPP delivery platform.

Current Investors

Lapam Capital, Puhong Capital, Longmen Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Epidemiology, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.stemirna.com

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.